AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Esperion:HC Wainwright Reiterates Buy, Raises PT to $16 from $15.50
ByAinvest
Friday, Sep 19, 2025 9:34 am ET1min read
Esperion:HC Wainwright Reiterates Buy, Raises PT to $16 from $15.50
Esperion Therapeutics, Inc. (NASDAQ: ESPR) experienced a significant 7.1% increase in its share price during mid-day trading on September 11, 2025, reaching a price of $2.79. This upward movement was despite a notable decline in trading volume, with only 1,282,316 shares traded compared to the average session volume of 4,934,244 shares.Analysts at HC Wainwright have maintained a positive stance on Esperion Therapeutics, reaffirming their "buy" rating and raising the price target to $16.00 from the previous $15.50. This positive sentiment contrasts with other analysts who have downgraded the stock to a "hold" rating, resulting in a consensus rating of "Moderate Buy" with an average price target of $7.00 [1].
Esperion Therapeutics, a biopharmaceutical company, specializes in developing and commercializing medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its marketed products, NEXLETOL and NEXLIZET, are oral, once-daily, non-statin medicines designed to treat primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease .
In the latest quarterly earnings report, Esperion Therapeutics reported earnings per share (EPS) of $0.02, beating the consensus estimate of $0.17 by $0.15. The company also reported revenue of $82.39 million, exceeding analysts' expectations of $62.55 million. Despite these positive earnings, the company had a negative net margin of 35.84% and a negative return on equity of 0.91% .
Several institutional investors have shown interest in Esperion Therapeutics, with Sivia Capital Partners LLC, North Star Investment Management Corp., Meridian Wealth Management LLC, Synergy Asset Management LLC, and Boomfish Wealth Group LLC all increasing their stakes in the company. Institutional investors and hedge funds currently own 47.39% of the stock .
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet